Innoviva Specialty Therapeutics at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Innoviva Specialty Therapeutics brings 4 presentations to IDWeek 2026 in Washington, and exhibits at Booth 515. Its program centres on Staphylococcus aureus bacteremia and on extending ceftobiprole to children through model-based dosing. It also reports that zoliflodacin keeps clearing urogenital gonorrhoea at high rates in patients also infected with chlamydia.
| Organization | IDWeek 2026 Attendance |
|---|---|
Innoviva Specialty Therapeutics Waltham, MA | |
Innoviva subsidiary developing and selling critical care and infectious disease medicines, including an antibiotic for Acinetobacter infections and a septic shock vasopressor. | Booth Exhibiting at Booth 515 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Wed Oct 21 11:00am–12:00pm The Evolving Management of S. aureus Bacteremia: 2026 Updates and Emerging Evidence Antimicrobials, resistance and stewardship Poster Thu Oct 22 12:15pm–1:30pm Pediatric Dose Selection of Ceftobiprole for Staphylococcus aureus Bacteremia, Including Right‑Sided Infective Endocarditis Using Model-Based Approaches Poster Sat Oct 24 12:15pm–1:30pm Extrapolation of Adult Efficacy and Safety to Support Pediatric Use of Ceftobiprole for Acute Bacterial Skin and Skin Structure Infections Talk Sat Oct 24 2:15pm–2:30pm Zoliflodacin Maintains High Rates of Microbiologic Eradication of Urogenital Neisseria gonorrhoeae in Patients Co-infected with Chlamydia trachomatis Antimicrobials, resistance and stewardshipHIV, sexually transmitted infections and viral hepatitis |
Instantly find 20 buyers from Innoviva Specialty Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction